ZVRA — Zevra Therapeutics Share News
0.000.00%
Last trade - 00:00- $613.43m
- $391.86m
- $106.47m
Zevra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Zevra Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Zevra Therapeutics To Report Third Quarter 2024 Financial Results
U.S. RESEARCH ROUNDUP-Costco Wholesale, McKesson, Starbucks
Brief: Zevra Therapeutics To Present Top-Line Data From The Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia At Sleep Europe 2024
Europe Research Roundup: Costco Wholesale, McKesson, Starbucks
Zevra Therapeutics prices rare genetic disorder drug at up to $106,000 per month (updated)
Zevra Therapeutics prices genetic disorder drug at up to $106,000 per month
Zevra Therapeutics rises on US FDA approval for rare genetic disease treatment
US FDA approves Zevra's treatment for rare genetic disease (updated)
Brief: Fda Approves Zevra's Miplyffa
US FDA approves Zevra's genetic disorder treatment
Zevra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Zevra Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Zevra Therapeutics Announces Pricing Of Underwritten Offering Of Common Stock
Brief: FDA Advisory Committee Votes Favorably That The Data Support Arimoclomol As Effective Treatment For Patients With Niemann-Pick Disease Type C
Brief: Zevra Therapeutics Says Entered Into An Equity Distribution Agreement With Citizens JMP Securities
Brief: Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Brief: Zevra Therapeutics Expands Executive Leadership Team